Veracyte Expands Urologic Cancer Data at ASCO GU Symposium with 15+ Abstracts — Veracyte, Inc.

Event summary

Veracyte to present over 15 abstracts at the 2026 ASCO GU Symposium, spanning prostate and bladder cancer studies.
Key focus on Decipher Prostate real-world data and new insights from phase II clinical trials for TrueMRD MIBC test.
SURE-02 trial highlights genomic subtyping with Decipher Bladder to guide treatment approaches in bladder cancer.
Oral presentation scheduled for TrueMRD MIBC test in HCRN GU 20-444 response guided bladder-sparing trial.
Conference takes place February 26-28, 2026, in San Francisco.

The big picture

Veracyte’s extensive data presentation at the ASCO GU Symposium underscores its strategic focus on advancing genomic testing in urologic cancers. The company is positioning itself as a key player in precision-based care, leveraging AI and whole-genome sequencing to guide clinical decision-making. This move aligns with broader industry trends towards personalized medicine and the increasing integration of molecular subtyping in cancer treatment protocols.

What we're watching

Clinical Validation: How the extensive data presentation will impact the clinical adoption of Veracyte’s Decipher and TrueMRD tests.
Market Differentiation: Whether Veracyte can sustain its leadership position in urologic cancer diagnostics amid growing competition.
Regulatory Approval: The pace at which TrueMRD MIBC test gains regulatory approval and commercialization post-conference.